Amneal Pharmaceuticals, Inc. filed a Form 8-K with the SEC on November 3, 2026, reporting its results of operations and financial condition for the third quarter ended September 30, 2026.

Key Highlights

  • Filing date: November 3, 2026, covering the third quarter ended September 30, 2026.
  • Press release attached: A press release announcing Q3 2026 results was furnished as Exhibit 99.1 and incorporated by reference.
  • Conference call scheduled: Amneal hosted a call and live webcast at 8:30 am Eastern Time on November 3, 2026, to discuss its results.
  • Signed by CFO: The filing was signed by Anastasios Konidaris, Executive Vice President and Chief Financial Officer, designated as Principal Financial and Accounting Officer.
  • Listed security: Class A Common Stock, par value $0.01 per share, trades under NASDAQ:AMRX on The Nasdaq Stock Market LLC.

Amneal Discloses Q3 2026 Operating Results via Current Report

Amneal Pharmaceuticals, Inc., a Delaware-incorporated pharmaceutical company headquartered at 400 Crossing Blvd, Bridgewater, NJ 08807, filed a current report on Form 8-K on November 3, 2026, under Item 2.02 (Results of Operations and Financial Condition). According to the filing, the company issued a press release on that date announcing its financial results for the third quarter ended September 30, 2026, which was furnished as Exhibit 99.1 and incorporated by reference into the report.

The filing also included a disclosure under Item 7.01 (Regulation FD Disclosure), noting that Amneal held a conference call and live webcast on the same day to discuss its quarterly results. The company's Class A Common Stock carries a par value of $0.01 per share and is registered under Commission File Number 001-38485. The filing was executed by Anastasios Konidaris in his capacity as Executive Vice President and Chief Financial Officer, who serves as the company's Principal Financial and Accounting Officer.

As is standard for disclosures furnished under Items 2.02 and 7.01, the filing states that the information "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934" and is "not otherwise subject to the liabilities of that section." The actual financial figures from Q3 2026 are contained in the attached press release, Exhibit 99.1, which is incorporated by reference but not reproduced in the body of the 8-K form itself.

What Was Disclosed

Amneal Pharmaceuticals filed a Form 8-K on November 3, 2026, furnishing its Q3 2026 earnings press release as Exhibit 99.1 and disclosing that a related investor conference call and webcast took place the same morning at 8:30 am Eastern Time.